ALZN Shares Outstanding History
Below is a table of the ALZN shares outstanding history going back to 6/15/2021:

Date ALZN Shares Outstanding

Also see: ALZN Market Cap History
ALZN Historical Shares Outstanding:
+8.14% CAGR
ALZN Historical Shares Outstanding: +8.14% CAGR

Mouse over chart for data details
6/15/2021 ...3/15/2022
Alzamend Neuro is a specialty pharmaceutical company engaged in the development and commercialization of patented intellectual property to prevent, treat and cure Alzheimer's disease ("Alzheimer's" or "AD"). Co. has licensed an immunotherapy vaccine peptide that works both as a treatment and vaccine against Alzheimer's and an ionic cocrystal of lithium to mitigate extreme agitation and forestall other deterioration as displayed by patients with up to moderate AD and possibly other neurodegenerative diseases. Co. devotes substantially all its efforts towards research and development of its Technology and raising capital. We show 5 historical shares outstanding datapoints in our coverage of ALZN's shares outstanding history.

Understanding the changing numbers of ALZN shares outstanding — and comprehending the concept of differing number of shares outstanding in general comparing companies like ALZN versus peers — is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies. Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history. With this page we aim to empower investors researching ALZN by allowing them to research ALZN shares outstanding history as well as any other stock in our coverage universe.
Quotes delayed 20 minutes

Email EnvelopeFree ALZN Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Shares Outstanding Importance

If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Alzamend Neuro (ALZN) is categorized under the Healthcare sector; to help you further research historical shares outstanding numbers, below are some other companies in the same sector:

AMAG Shares Outstanding History
AMDA Shares Outstanding History
AMED Shares Outstanding History
AMEH Shares Outstanding History
AMGN Shares Outstanding History
AMN Shares Outstanding History
AMPH Shares Outstanding History
AMRX Shares Outstanding History
AMTI Shares Outstanding History
ANAB Shares Outstanding History
More Healthcare companies »


ALZN Shares Outstanding History | | Copyright © 2017 - 2022, All Rights Reserved

Nothing in is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.